Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: MIS18A

Gene summary for MIS18A

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

MIS18A

Gene ID

54069

Gene nameMIS18 kinetochore protein A
Gene AliasB28
Cytomap21q22.11
Gene Typeprotein-coding
GO ID

GO:0006139

UniProtAcc

Q9NYP9


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
54069MIS18ALZE7THumanEsophagusESCC4.85e-043.57e-010.0667
54069MIS18ALZE20THumanEsophagusESCC2.66e-049.52e-020.0662
54069MIS18ALZE24THumanEsophagusESCC2.17e-036.29e-020.0596
54069MIS18AP1T-EHumanEsophagusESCC2.03e-042.20e-010.0875
54069MIS18AP2T-EHumanEsophagusESCC1.96e-255.34e-010.1177
54069MIS18AP4T-EHumanEsophagusESCC3.25e-369.00e-010.1323
54069MIS18AP5T-EHumanEsophagusESCC1.98e-194.42e-010.1327
54069MIS18AP8T-EHumanEsophagusESCC2.65e-131.55e-010.0889
54069MIS18AP9T-EHumanEsophagusESCC8.71e-051.57e-010.1131
54069MIS18AP10T-EHumanEsophagusESCC7.84e-244.82e-010.116
54069MIS18AP11T-EHumanEsophagusESCC2.04e-041.20e-010.1426
54069MIS18AP12T-EHumanEsophagusESCC1.10e-152.54e-010.1122
54069MIS18AP15T-EHumanEsophagusESCC4.23e-051.23e-010.1149
54069MIS18AP16T-EHumanEsophagusESCC1.56e-143.18e-010.1153
54069MIS18AP17T-EHumanEsophagusESCC3.86e-081.96e-010.1278
54069MIS18AP21T-EHumanEsophagusESCC2.33e-142.52e-010.1617
54069MIS18AP22T-EHumanEsophagusESCC5.86e-122.63e-010.1236
54069MIS18AP23T-EHumanEsophagusESCC3.38e-081.77e-010.108
54069MIS18AP24T-EHumanEsophagusESCC2.09e-092.03e-010.1287
54069MIS18AP26T-EHumanEsophagusESCC8.15e-132.74e-010.1276
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000705911EsophagusESCCchromosome segregation238/8552346/187231.72e-181.82e-16238
GO:005105215EsophagusESCCregulation of DNA metabolic process232/8552359/187232.40e-131.13e-11232
GO:00434143EsophagusESCCmacromolecule methylation199/8552316/187233.44e-109.57e-09199
GO:00322592EsophagusESCCmethylation222/8552364/187232.26e-095.09e-08222
GO:000632517EsophagusESCCchromatin organization240/8552409/187236.52e-081.14e-06240
GO:00345081EsophagusESCCcentromere complex assembly25/855230/187232.45e-052.09e-0425
GO:0031055EsophagusESCCchromatin remodeling at centromere9/855210/187235.09e-031.92e-029
GO:0043486EsophagusESCChistone exchange16/855222/187239.46e-033.28e-0216
GO:0006304EsophagusESCCDNA modification68/8552120/187239.95e-033.42e-0268
GO:00070592Oral cavityOSCCchromosome segregation206/7305346/187235.82e-153.76e-13206
GO:005105210Oral cavityOSCCregulation of DNA metabolic process207/7305359/187234.45e-132.17e-11207
GO:0034508Oral cavityOSCCcentromere complex assembly21/730530/187235.75e-043.30e-0321
GO:000632510Oral cavityOSCCchromatin organization190/7305409/187231.17e-035.97e-03190
GO:00434142Oral cavityOSCCmacromolecule methylation149/7305316/187231.82e-038.60e-03149
GO:00322591Oral cavityOSCCmethylation168/7305364/187233.03e-031.31e-02168
GO:005105213Oral cavityLPregulation of DNA metabolic process125/4623359/187239.43e-061.75e-04125
GO:00070591Oral cavityLPchromosome segregation117/4623346/187237.61e-059.91e-04117
GO:005105218ThyroidPTCregulation of DNA metabolic process171/5968359/187232.52e-108.33e-09171
GO:000632520ThyroidPTCchromatin organization183/5968409/187232.55e-085.70e-07183
GO:00070595ThyroidPTCchromosome segregation146/5968346/187232.99e-052.87e-04146
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
MIS18ASNVMissense_Mutationrs764293569c.424G>Ap.Ala142Thrp.A142TQ9NYP9protein_codingtolerated(0.9)benign(0)TCGA-A6-5661-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
MIS18ASNVMissense_Mutationc.656T>Gp.Leu219Argp.L219RQ9NYP9protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A6-6781-01Colorectumcolon adenocarcinomaMale<65III/IVChemotherapyoxaliplatinSD
MIS18ASNVMissense_Mutationc.122N>Ap.Arg41Hisp.R41HQ9NYP9protein_codingtolerated_low_confidence(0.06)benign(0.067)TCGA-AD-5900-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
MIS18ASNVMissense_Mutationrs754925175c.464N>Tp.Thr155Metp.T155MQ9NYP9protein_codingdeleterious(0)probably_damaging(0.999)TCGA-A5-A3LO-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapycarboplatinSD
MIS18ASNVMissense_Mutationnovelc.35G>Ap.Gly12Glup.G12EQ9NYP9protein_codingtolerated_low_confidence(0.3)benign(0.01)TCGA-AP-A054-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinPD
MIS18ASNVMissense_Mutationc.122N>Ap.Arg41Hisp.R41HQ9NYP9protein_codingtolerated_low_confidence(0.06)benign(0.067)TCGA-AX-A1C4-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
MIS18ASNVMissense_Mutationnovelc.98N>Gp.Lys33Argp.K33RQ9NYP9protein_codingtolerated_low_confidence(0.93)benign(0.003)TCGA-EO-A3KX-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
MIS18ASNVMissense_Mutationnovelc.213N>Tp.Glu71Aspp.E71DQ9NYP9protein_codingtolerated(0.15)benign(0.04)TCGA-99-8032-01Lunglung adenocarcinomaMale<65I/IIUnknownUnknownSD
MIS18ASNVMissense_Mutationc.511N>Ap.Glu171Lysp.E171KQ9NYP9protein_codingtolerated(0.25)benign(0.153)TCGA-60-2698-01Lunglung squamous cell carcinomaMale<65I/IIChemotherapymithramycinPD
MIS18AinsertionFrame_Shift_Insnovelc.644_645insCACTATGTTGCTTCATTTAp.Leu215PhefsTer24p.L215Ffs*24Q9NYP9protein_codingTCGA-56-8504-01Lunglung squamous cell carcinomaMale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1